Regulatory barriers are forcing drug discovery to move to China
Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China? As in many other industries, it’s so much cheaper to synthesize new compounds inside Chinese biotechnology firms once a novel […]
Buy them and shut them down
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Health care investor Kevin Tang buys “zombie” biotechs to shut them down. It’s a counterintuitive, but ingenious solution to the sector’s intractable problem covered in last week’s newsletter. Tang’s disposal service is not a […]
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, […]
How to Ride the Biotech Roller Coaster
With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs. But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech […]